Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 05, 2015 1:00 AM ET


Company Overview of Aclaris Therapeutics, Inc.

Company Overview

Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.

101 Lindenwood Drive

Suite 400

Malvern, PA 19355

United States

Founded in 2012

10 Employees





Key Executives for Aclaris Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 45
Chief Financial Officer and Secretary
Age: 49
Chief Operating Officer
Age: 56
Chief Legal Officer and Assistant Secretary
Age: 56
Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.

Aclaris Therapeutics, Inc. Key Developments

Aclaris Therapeutics Seeks Acquisitions

Aclaris Therapeutics, Inc. intends to use the net proceeds from IPO to acquire additional drug candidates.

Aclaris Therapeutics, Inc. Announces Statistically Significant Results from Phase 2 Clinical Trial of Its Lead Drug Candidate, A-101

Aclaris Therapeutics, Inc. announced statistically significant results from a Phase 2 clinical trial of its lead drug candidate, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face. SK is one of the most common types of skin tumors. Although the lesions are benign, many patients elect to have SK treated, either because the lesions have become irritated or because the patient feels they are cosmetically concerning. The double-blind, vehicle-controlled Phase 2 clinical trial was designed to evaluate the safety, tolerability and effectiveness of A-101 in removing targeted SK lesions on the face. The trial used a parallel-group design to compare two concentrations of A-101 and vehicle (placebo) in 120 subjects with SK lesions on the face. Results from the trial showed A-101 achieved statistical significance in clearing SK lesions in a dose-related fashion. A-101 was well tolerated at both concentrations studied. SK are among the most common skin tumors seen in middle-aged and older adults, affecting over 83 million people in the United States.i SK lesions have a waxy, scaly, slightly elevated appearance and often multiple growths are present. Currently, SK lesions are treated using modalities such as cryosurgery, electrosurgery, curettage, or surgical removal which may be painful and may often result in pigmentary changes and/or scarring at the treatment site.

Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM

Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Neal Walker, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Springbac Worldwide, LLC United States
Forest Laboratories, LLC United States
Amgen Clinical Partners, L.P. United States
Lifetech Enterprises, Inc. United States
Cytos Pharmaceuticals L.L.C. United States

Recent Private Companies Transactions

Private Placement
August 28, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aclaris Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at